Masaomi Tajimi
Kobe, 6510086, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Disease management landscape in patients with mantle cell lymphoma in Japan: a real-world study.
Journal: Future oncology (London, England)
Published: September 08, 2025
Treatment selection and influencing factors for chronic lymphocytic leukemia: a physician survey in Japan.
Journal: International journal of clinical oncology
Published: July 16, 2024
Patient perspectives on treatment for mantle cell lymphoma and chronic lymphocytic leukemia in Japan.
Journal: Journal of clinical and experimental hematopathology : JCEH
Published: May 15, 2024
Treatment patterns in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post covalent Bruton tyrosine kinase inhibitor treatment: a Japanese claims database study.
Journal: Journal of clinical and experimental hematopathology : JCEH
Published: December 26, 2023
Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database.
Journal: Advances in therapy
Published: March 25, 2022
Correction to: Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.
Journal: Investigational new drugs
Published: September 07, 2020
A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors.
Journal: Investigational new drugs
Published: July 30, 2020
Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer.
Journal: Investigational new drugs
Published: February 07, 2020
A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.
Journal: Investigational new drugs
Published: May 07, 2018
A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors.
Journal: Investigational new drugs
Published: August 03, 2017
PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay.
Journal: Japanese journal of clinical oncology
Published: July 27, 2017
Last Updated: 09/26/2026